Do SGLT2 inhibitors improve functional capacity and quality of life in patients with heart failure?
SGLT2 inhibitors improve functional capacity and quality of life in heart failure patients across the spectrum of ejection fraction.
These findings suggest that in addition to known clinical associations with mortality and hospitalization outcomes, SGLT2i use is associated with improvement in outcomes of interest to patients' everyday lives as measured by objective assessments of maximal exercise capacity and validated QOL questionnaires, regardless of sex or ejection fraction.
Gao et al. (2024) studied this question.